El Derecho a la verdad de las víctimas en el acuerdo final para la terminación del conflicto y la construcción de una paz estable y duradera

Artículo de reflexiónEn este artículo se efectúa un análisis de las garantías al derecho a la verdad que se han consagrado en el acuerdo final, firmado en el Teatro Colón, para la terminación del conflicto armado en Colombia. Este análisis se desarrolla contrastando el contenido del derecho a la verdad de las victimas dentro del acuerdo final, con los Principios para la lucha contra la impunidad o Principios Joinet, para determinar si dicho acuerdo se adecua a estos principios.56 p.INTRODUCCIÓN 1. DERECHO A LA VERDAD 2. DERECHO A LA VERDAD DE LAS VÍCTIMAS EN EL ACUERDO FINAL 3. TRIBUNALES DE LA VERDAD 4. CONJUNTO DE PRINCIPIOS ACTUALIZADO PARA LA PROTECCIÓN Y LA PROMOCIÓN DE LOS DERECHOS HUMANOS MEDIANTE LA LUCHA CONTRA LA IMPUNIDAD 5. ANÁLISIS DEL DERECHO A LA VERDAD EN EL ACUERDO FINAL A LA LUZ DE LOS PRINCIPIOS JOINET CONCLUSIONES REFERENCIASPregradoAbogad

Predictive Power of the "Trigger Tool" for the detection of adverse events in general surgery: a multicenter observational validation study

Background In spite of the global implementation of standardized surgical safety checklists and evidence-based practices, general surgery remains associated with a high residual risk of preventable perioperative complications and adverse events. This study was designed to validate the hypothesis that a new “Trigger Tool” represents a sensitive predictor of adverse events in general surgery. Methods An observational multicenter validation study was performed among 31 hospitals in Spain. The previously described “Trigger Tool” based on 40 specific triggers was applied to validate the predictive power of predicting adverse events in the perioperative care of surgical patients. A prediction model was used by means of a binary logistic regression analysis. Results The prevalence of adverse events among a total of 1,132 surgical cases included in this study was 31.53%. The “Trigger Tool” had a sensitivity and specificity of 86.27% and 79.55% respectively for predicting these adverse events. A total of 12 selected triggers of overall 40 triggers were identified for optimizing the predictive power of the “Trigger Tool”. Conclusions The “Trigger Tool” has a high predictive capacity for predicting adverse events in surgical procedures. We recommend a revision of the original 40 triggers to 12 selected triggers to optimize the predictive power of this tool, which will have to be validated in future studies

El turismo cultural, una apuesta articuladora para el desarrollo sostenible de la región Pacífico

El presente documento se constituye como un aporte, especialmente de la academia de la región Pacífico, y tiene como propósito evidenciar la situación actual del turismo cultural y las acciones que se requieren para construir una política pública que contribuya a mejorar las condiciones territoriales, gestionando ante el sector público y privado la solución del problema identificado que se refiere a “la débil gestión competitiva del turismo cultural sostenible en la región Pacífico” (Paredes y Isaziga, 2020), por intermedio de la Región Administrativa y de Planificación- RAP Pacífico. Como técnica de recolección de datos, se propone el análisis documental, conocido como el “estudio de los documentos impresos y no impresos, lo cual contribuye a la comprensión de problemas sociales, de hechos sociológicos, antropológicos, psicológicos o educativos a los que se refieren” (Universidad de Ibagué, 2009)

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients : the SOLID study

At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using enzyme-linked immunosorbent assay (ELISA) kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARS-CoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Of 1,500 patients, 128 were seropositive, overall prevalence of 8.5% seropositivity [95% confidence interval (CI): 7.2-10.1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38.8-56.6%). A second determination was performed on average 4.5 months later [interquartile range (IQR), 4.0-5.0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% of patients. The severity of the infection, the need for hospitalization (P=0.032) and the presence of symptoms at diagnosis (P=0.02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. ClinicalTrials.gov identifier: NCT04407143

Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab0)2] antivenoms, in Bothrops asper bites in Colombia

2082-02 Embargo por política editorialThe efficacy and safety of two polyvalent horse-derived antivenoms in Bothrops asper envenomings were tested in a randomized, double-blind, clinical trial performed in Colombia. Both antivenoms were manufactured from the same pool of hyperimmune plasma. Antivenom A was made of F(ab′)2 fragments, generated by pepsin digestion and caprylic acid precipitation, whereas antivenom B consisted of whole IgG molecules produced by caprylic acid precipitation followed by ion-exchange chromatography. Besides the different nature of the active substance, antivenom B had higher protein concentration, slightly higher turbidity and aggregate content. No significant differences were observed in the efficacy of antivenoms. Both halted local and systemic bleeding (P = 0.40) within 6–12 h of treatment in 100% of the cases, and restored blood coagulation (P = 0.87) within 6–24 h in 84.7% of patients, and within 48 h in all of them, in agreement with restoration of plasma fibrinogen concentration. Venom concentrations in serum dropped significantly (P < 0.001), to very low levels, 1 h after antivenom infusion. Nevertheless, eight patients (11.1%), four for each antivenom, presented recurrence of venom antigenaemia at different times, from 6 to 96 h, with clinical significance (recurrent coagulopathy) only in one group B patient (2.9%). Serum creatine kinase (CK) activity was increased, as a consequence of local myonecrosis. There was no significant difference (P = 0.51) in the incidence of early adverse reactions to antivenom administration (28.9% for patients of group A and 20.6% for patients of group B), most of the reactions being mild, mainly cutaneous. The most frequent complications were cellulitis (16.7%), abscess formation (5.6%), acute renal failure (8.3%), and compartmental syndrome (5.6%). In conclusion, IgG and F(ab′)2 antivenoms, prepared by caprylic acid fractionation, presented similar efficacy and safety profiles for the treatment of B. asper envenomings in Colombia.Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología Francisco José de Caldas//Colciencias/ColombiaUniversidad de Antioquia///ColombiaPrograma Iberoamericano de Ciencia y Tecnología para el Desarrollo/[206AC0281]/CYTED/EspañaUniversidad de Costa Rica/[741-A9-003]/UCR/Costa RicaUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.

At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using enzyme-linked immunosorbent assay (ELISA) kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARS-CoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Of 1,500 patients, 128 were seropositive, overall prevalence of 8.5% seropositivity [95% confidence interval (CI): 7.2-10.1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38.8-56.6%). A second determination was performed on average 4.5 months later [interquartile range (IQR), 4.0-5.0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% of patients. The severity of the infection, the need for hospitalization (P=0.032) and the presence of symptoms at diagnosis (P=0.02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. ClinicalTrials.gov identifier: NCT04407143

Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without β-propiolactone, in the treatment of Bothrops asper bites in Colombia

The efficacy and safety of two whole IgG polyvalent antivenoms (A and B) were compared in a randomised, blinded clinical trial in 67 patients systemically envenomed by Bothrops asper in Colombia. Both antivenoms were fractionated by caprylic acid precipitation and had similar neutralising potencies, protein concentrations and aggregate contents. Antivenom B was additionally treated with β-propiolactone to lower its anticomplementary activity. Analysing all treatment regimens together, there were no significant differences between the two antivenoms (A = 34 patients; B = 33 patients) in the time taken to reverse venom-induced bleeding and coagulopathy, to restore physiological fibrinogen concentrations and to clear serum venom antigenaemia. Blood coagulability was restored within 6–24 h in 97% of patients, all of whom had normal coagulation and plasma fibrinogen levels 48 h after the start of antivenom treatment. Two patients (3.0%) had recurrent coagulopathy and eight patients suffered recurrence of antigenaemia within 72 h of treatment. None of the dosage regimens of either antivenom used guaranteed resolution of venom-induced coagulopathy within 6 h, nor did they prevent recurrences. A further dose of antivenom at 6 h also did not guarantee resolution of coagulopathy within 12–24 h in all patients. The incidence of early adverse reactions (all mild) was similar for both antivenoms (15% and 24%; P > 0.05).Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología Francisco José de Caldas//COLCIENCIAS/ColombiaUniversidad de Antioquia/[206PI0281]/CYTED/ColombiaUniversidad de Costa Rica//UCR/Costa RicaUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP

Experiencias de Aprendizaje-Servicio en la UPM: 2021 y 2022

La Oficina de Aprendizaje-Servicio (ApS) de la UPM, constituida en sesión del Consejo de Gobierno de diciembre de 2019 tiene, como misión fundamental, promover en el ámbito de las enseñanzas de esta universidad la metodología ApS. Con esta finalidad se vienen realizando convocatorias de proyectos de impacto social alineados con los ODS como un mecanismo más para la contribución a la Agenda 2030, y se colabora intensamente con las diversas oficinas constituidas con el mismo objetivo en otras universidades. Nuestra oficina pretende impulsar progresivamente la colaboración con entidades ajenas a la UPM, y atender demandas y necesidades sociales en las que nuestros estudiantes y profesores brinden sus conocimientos para la construcción de una mejor y más justa sociedad. Con este propósito, se han puesto en marcha numerosas iniciativas y colaboraciones con Ayuntamientos, Asociaciones, ONG, Fundaciones y centros de enseñanza, con el fin común de plantear mejoras y trabajar con entornos desfavorecidos, y colectivos vulnerables de nuestro entorno. Cabe destacar la muy positiva acogida que, progresivamente se está logrando, en lo relativo a la diseminación de estas iniciativas en el ámbito de la UPM, viéndose incrementada la participación e interés de nuestros docentes y estudiantes en los llamamientos que se realizan desde la oficina. Desde la constitución de la oficina, son ya más de 100 actividades desarrolladas con la participación de más de 500 profesores. Uno de los compromisos de la Oficina ApS de la UPM es dar visibilidad por su carácter meritorio a las experiencias realizadas por el profesorado y los estudiantes de nuestra universidad y, es por ello, que nos complace la presentación de esta primera edición del ebook, en el que se recogen algunas de las experiencias realizadas en nuestra universidad y que confiamos ampliar periódicamente con futuras ediciones. Nuestro más sincero agradecimiento a todos los profesores que habéis hecho posible esta primera publicación con vuestras contribuciones

Quarterly Report: Implementation Status of the Colombian Final Peace Accord, July-September 2023

On a quarterly basis, the Kroc Institute produces independent, impartial, and academically rigorous information on the status of the implementation of the Final Accord. The quarterly reports aim to promote implementation processes and public dialogue and are presented to government and non-government entities in charge of implementation, civil society organizations, the international community, and all other parties committed or interested in this process.</p

Biodiversidad 2015. Estado y tendencias de la biodiversidad continental de Colombia

El propósito de este documento es fortalecer la capacidad de agentes públicos y privados para la aplicación de la PNGIBSE, que constituye en sí misma una apuesta de interfaz entre ciencia, política y sociedad en la perspectiva de construir sostenibilidad en el desarrollo. Además de ello, representa un insumo para el seguimiento a los compromisos del país frente a convenios e iniciativas internacionales (CDB, IPBES, OCDE), así como un mecanismo pedagógico para generar interés, conciencia y apropiación de las diferentes dimensiones de la biodiversidad del país.Bogotá, D. C., ColombiaInstituto de Investigación de Recursos Biológicos Alexander von Humboldtreporte.humboldt.org.coreporte.humboldt.org.co/biodiversidad/en